Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

24,258 signal articles · 45 in last 24h · 115,243 total before filter · latest 1h ago
45last 24h
1804last 7d
299● bullish (7d)
171● bearish (7d)
205publishers
AllMacro322Earnings851M&A105Regulatory25Product16Analyst25
✕ clear all filtersticker: NVOSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?
Insider Monkey5d agoneutral
Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?

The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one of healthcare’s fastest-growing markets. Yet another competitive advantage for investors to […]

LLYNVO
Novo Nordisk (CPSE:NOVO B) Wins Dutch Injunction Over Compounded Semaglutide Spray
Simply Wall St.7d agobullish
Novo Nordisk (CPSE:NOVO B) Wins Dutch Injunction Over Compounded Semaglutide Spray

Novo Nordisk (CPSE:NOVO B) secured a Dutch court injunction against Ceban Ziekenhuisfarmacie over an unapproved compounded semaglutide nasal spray. The ruling blocks production and distribution of the compounded nasal spray in the Netherlands for infringing Novo Nordisk's semaglutide patent. The decision reinforces Novo Nordisk's intellectual property position around Wegovy, Ozempic and Rybelsus and limits non approved competitor versions. Patent enforcement around key obesity and diabetes...

NVO
Novo Nordisk A/S Q2 Earnings Call Highlights
MarketBeat7d agoneutral
Novo Nordisk A/S Q2 Earnings Call Highlights

Novo Nordisk A/S (NYSE:NVO) reported second-quarter adjusted sales growth of 7% at constant exchange rates, supported by GLP-1 volume growth across its obesity and diabetes franchises, while lower realized prices and manufacturing-related costs weighed on margins. Chief Executive Officer Mike Doust

HIMSNVO
The Week in Numbers: BP's huge profit, Toyota moves fast
Reuters Videos8d agoneutralVIDEO
The Week in Numbers: BP's huge profit, Toyota moves fast

<body><p>STORY: From BP making huge profits to Toyota's raised forecast... This is the Week in Numbers.&nbsp;</p><p>:: Week in Numbers&nbsp;</p><p>:: $5.73 billion</p><p>$5.73 billion was how high BP's second-quarter profit reached.</p><p>The British energy major cited higher energy prices, trading and refining margins.</p><p>Oil giants have scored big this year from market volatility caused by the U.S.-Iran war.</p><p>BP rival Shell also reported a doubling of second-quarter profit a week before.</p><p>:: 12%</p><p>About 12% was how much SpaceX shares dropped by after its first-ever earnings call as a public company.</p><p>Investors were worried about heavy AI spending on data centers and Nvidia chips.</p><p>Quarterly capital spending on AI reached $15.8 billion.</p><p>Elon Musk's rocket company said the economics of the investments were improving, but suggested AI investments would stay elevated.</p><p>:: $497 million</p><p>$497 million was the sales figure for Novo Nordisk's Wegovy pill.</p><p>That disappointed investors as it just missed expectations.</p><p>Shares dropped despite the Danish drugmaker raising its full-year profit and sales outlook.</p><p>Novo is battling to regain ground from U.S. rival Eli Lilly in the obesity drug market.</p><p>:: 10%</p><p>More than 10% is how far Lufthansa shares fell during the week.</p><p>Investors sold off after the German airline cut its profit outlook.</p><p>It further warned earnings could fall this year after the Iran war drove up fuel costs.</p><p>The warning showed the pressure European airlines face due to higher jet fuel costs.</p><p>:: $6.3 billion</p><p>$6.3 billion was the size of the share buyback announced by Toyota.</p><p>The world's biggest automaker also raised its annual operating profit forecast by 13%.</p><p>But Toyota also reported a 9% slide in first-quarter profit - its fifth straight quarter of declines.</p><p>It was hit by falling sales in China while the Iran war also raised costs for raw materials and parts.</p></body>

NVDANVO
Novo Nordisk CEO resets expectations for Wegovy's explosive growth
TheStreet8d agoneutral
Novo Nordisk CEO resets expectations for Wegovy's explosive growth

I believe that when a stock is down nearly 10% year to date and down 38% over three years, the CEO's job on a quarterly earnings call is not just to report results. It is to rebuild a narrative that investors have lost confidence in. And Novo Nordisk CEO Mike Doustdar is honestly trying that with ...

NVO
Lexicon Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat9d agoneutral
Lexicon Pharmaceuticals Q2 Earnings Call Highlights

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III SONATA-HCM trial and outlined plans to resubmit a new drug application for ZYNQUISTA in type 1 diabet

NVO
How Novo Nordisk’s CEO Says He Is Shifting the Company’s Perspective
The Wall Street Journal9d agoneutral
How Novo Nordisk’s CEO Says He Is Shifting the Company’s Perspective

Doustdar was fairly fresh off an earnings call, but we connected to discuss a different milestone—his one-year anniversary in the CEO role, which is tomorrow. Introducing culture change had been part of the CEO’s mission since he landed the job, and he arrived with notes, having already worked at Novo Nordisk for 33 years.

NVO